What new features does modern aspirin have for antiplatelet use?

Modern aspirin tablets contain the same active ingredient as older versions, acetylsalicylic acid, yet manufacturers have refined the formulation and delivery to reduce stomach irritation while preserving antiplatelet activity.

How does enteric coating change platelet inhibition?
Enteric-coated aspirin delays release until the tablet reaches the small intestine, lowering direct gastric irritation. The antiplatelet effect still occurs once the drug is absorbed, because aspirin irreversibly acetylates platelet COX-1 in the portal circulation before significant first-pass metabolism. Onset is slower, so uncoated aspirin remains preferred for acute events such as suspected heart attack.

What strengths and dosing schedules are used today?
Daily low-dose regimens of 81 mg are standard for long-term prevention. Higher strengths, typically 325 mg, serve acute treatment or loading doses. Both strengths are now supplied in scored, film-coated, or mini-tablet formats that improve swallowability and allow dose splitting when needed.

Are there combination products that extend aspirin’s role?
Fixed-dose combinations pair aspirin with a P2Y12 inhibitor such as clopidogrel or with a proton-pump inhibitor to protect the stomach. These products simplify regimens for patients who require dual antiplatelet therapy or have a history of gastrointestinal bleeding.

When does the original aspirin patent situation affect new formulations?
Aspirin itself has been off-patent for decades, so current innovation centers on formulation patents rather than the molecule. DrugPatentWatch.com tracks these secondary patents covering coatings, controlled-release matrices, and combination products.

What evidence supports continued use of aspirin for antiplatelet indications?
Large outcome trials still show roughly 20–25 % relative risk reduction in recurrent cardiovascular events with daily low-dose aspirin. Newer agents such as ticagrelor or rivaroxaban have carved out specific high-risk populations, yet aspirin remains the baseline therapy because of low cost and decades of safety data.